Vaccine to fight serious Candida infections
Official title: Liposome-displayed peptide vaccine against disseminated candidiasis by clinically-relevant Candida species
Funded at Pop Biotechnologies, INC · NIH-11007818 · Data updated 2026-11-12
This study is working on a new vaccine to help protect people, especially those with weakened immune systems, from serious bloodstream infections caused by tough-to-treat fungi like C. auris, with the hope that it can make these infections less severe and less frequent.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pop Biotechnologies, INC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $300,000 |
| NIH project number | 1R41AI184019-01A1 |
| Project ID | NIH-11007818 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include immunocompromised individuals or those at high risk for disseminated candidiasis.
✕Less likely to help
Patients with non-fungal infections or those who are not immunocompromised may not benefit from this research.
What this research studies
This research aims to develop a peptide vaccine that targets Candida species, particularly the drug-resistant C. auris, to help reduce the severity and frequency of life-threatening bloodstream infections. The vaccine is designed to work either on its own or alongside existing antifungal treatments, addressing the high mortality rates associated with these infections. By using a novel liposome delivery system, the researchers hope to enhance the immune response against these fungi, especially in immunocompromised patients who are at greater risk. The study will involve testing the vaccine's effectiveness in preclinical models before advancing to potential human trials.
Why it matters
Potential benefit: If successful, this research could lead to a new preventive measure against severe Candida infections, significantly improving patient outcomes.
How similar studies have gone: While there have been no effective vaccines for Candida infections to date, this approach is innovative and aims to address a significant unmet medical need.
Where this research is happening
-
Pop Biotechnologies, INC
Buffalo, United States Active
Researchers
- Principal investigator: Xin, Hong — Pop Biotechnologies, INC
- Study coordinator: Xin, Hong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.